AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 141 min read$LQDA

Khindri Sanjeev sold $31K of LQDA

Khindri Sanjeev (Chief Development Officer) sold 1,101 shares of Liquidia Corp (LQDA) at $28.48 on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Khindri Sanjeev
Published Oct 14, 2026, 12:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

While the transaction size is modest, it adds transparency and may be factored into short‑term trading decisions.

02

Market read

A routine insider sale with limited price impact; primarily of interest to short‑term traders monitoring insider activity.

03

What to watch

Potential upcoming clinical trial milestones that could offset the negative signal.

Relevance 2/10Novelty 2/10Timing: post-market filing on 2026-10-13

Background

Form 4 disclosures provide the first public record of insider transactions, required by the SEC.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Chief Development Officer sold 1,101 shares for $31,356, a routine Form 4 filing.

Expected impact

possible modest pressure as the market prices in the insider sell

Evidence & confidence

The sale is small relative to holdings and market cap, so impact is limited but could signal minor negative sentiment.

Market effects

Sector

Minimal effect on the biotech sector; typical insider sales are not sector drivers.

Regional

No regional impact; the filing is company‑specific.

Global

Limited to investors tracking Liquidia Corp.

Counterpoint

What could challenge this read

The sale could be unrelated to fundamentals; the stock may still be undervalued.

Key entities

  • Company
    Liquidia Corp

    US‑listed biotech company (NASDAQ:LQDA).

  • Person
    Khindri Sanjeev

    Chief Development Officer of Liquidia Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

OCT 20
$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

news.alphastreet.com1 min
OCT 16
$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

biobuzz.io7 min
OCT 15
$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.

investing.com2 min